抗CXCR4联合抗PD-1免疫治疗通过调节胶质母细胞瘤微环境免疫细胞提供生存获益
该研究在GL261-Luc+小鼠胶质瘤模型中比较对照组、抗PD-1单药、抗CXCR4单药及两药联合的疗效。联合治疗较对照组和单药组显著改善生存,伴免疫记忆、免疫抑制性肿瘤浸润白细胞减少、脑内CD4+/CD8+比值改善及促炎细胞因子升高。提示靶向髓系细胞可增强抗PD-1抗肿瘤免疫。
要点
- 抗CXCR4联合抗PD-1在鼠胶质瘤模型中较单药和对照显著改善生存
- 联合治疗减少单核髓源性抑制细胞和小胶质细胞等免疫抑制细胞
- 联合治疗改善脑内CD4+/CD8+比值并升高促炎细胞因子
核心结论
- 抗CXCR4联合抗PD-1免疫治疗可调节胶质瘤微环境肿瘤浸润细胞群并改善生存率。
研究设计与样本
- C57BL/6小鼠植入GL261-Luc+胶质瘤细胞后随机分为对照、抗PD-1、抗CXCR4及联合治疗4组。
主要发现
- 联合治疗较对照组和单药组均带来显著生存获益。
- 联合治疗组小鼠表现出免疫记忆。
- 联合治疗减少脑内单核髓源性抑制细胞和小胶质细胞等免疫抑制性肿瘤浸润白细胞。
- 联合治疗改善脑内CD4+/CD8+比值并增加促炎细胞因子水平。
临床怎么用
- 靶向髓系细胞的抗CXCR4可能增强抗PD-1在胶质母细胞瘤中的抗肿瘤免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging evidence suggests that myeloid cells play a critical role in glioblastoma (GBM) immunosuppression. Disappointing results of recent checkpoint inhibitor trials suggest that combination immunotherapy with alternative agents could be fruitful in overcoming immunosuppression. Overexpression of chemokine receptor CXCR4 is associated with poor prognosis in GBM. We investigate the treatment effects of combination immunotherapy with anti-PD-1 and anti-CXCR4 in a murine glioma model. METHODS: C57BL/6 mice were implanted with GL261-Luc+ glioma cells and randomized into 4 arms: (1) control (2) anti-PD-1 (3) anti-CXCR4, and (4) anti-PD-1 and anti-CXCR4 therapy. Overall survival and median survival were assessed. Cell populations were assessed by flow cytometry. RESULTS: Combination therapy conferred a significant survival benefit compared to control and monotherapy arms. Mice that received combination therapy demonstrated immune memory and decreased populations of immunosuppressive tumor-infiltrating leukocytes, such as monocytic myeloid-derived suppressor cells and microglia within the brain. Furthermore, combination therapy improved CD4+/CD8+ ratios in the brain as well as contributed to increased levels of pro-inflammatory cytokines. CONCLUSIONS: Anti-CXCR4 and anti-PD-1 combination immunotherapy modulates tumor-infiltrating populations of the glioma microenvironment. Targeting myeloid cells with anti-CXCR4 facilitates anti-PD-1 to promote an antitumor immune response and improved survival rates.
引用
- Wu A, Maxwell R, Xia Y, et al. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J Neurooncol. 2019. PMID: 31025274. doi:10.1007/s11060-019-03172-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。